Analyst Ratings for Summit Therapeutics plc (SMMT)
SMMT Rating Summary
SMMT Price Target Summary
- Highest: $45.00 (Stifel)
- Lowest: $7.70 (Bernstein SocGen Group)
- Average: $29.25
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$29.25 (+112.7%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
Avg. $ Target:
$29.25 (+112.7%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/22/2026 | H.C. Wainwright | Mitchell S. Kapoor | Downgrade | Neutral (Buy) |
N/A (N/A) |
17.47 (13.75) |
-21.29% | Details |
| 5/21/2026 | Bernstein SocGen Group » Updated 6/1/2026 |
Jeffrey Walch | New Coverage | Underperform (N/A) |
7.70 (N/A) |
17.89 (13.75) |
-23.14% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
